155 related articles for article (PubMed ID: 37244751)
21. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
Shigemura K; Arbiser JL; Sun SY; Zayzafoon M; Johnstone PA; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LW
Cancer; 2007 Apr; 109(7):1279-89. PubMed ID: 17326044
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
24. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
Ignatoski KM; Escara-Wilke JF; Dai JL; Lui A; Dougall W; Daignault S; Yao Z; Zhang J; Day ML; Sargent EE; Keller ET
Prostate; 2008 Jun; 68(8):820-9. PubMed ID: 18324676
[TBL] [Abstract][Full Text] [Related]
25. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
[TBL] [Abstract][Full Text] [Related]
26. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
27. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
28. Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference.
Fu YK; Wang BJ; Tseng JC; Huang SH; Lin CY; Kuo YY; Hour TC; Chuu CP
J Biomed Sci; 2022 Feb; 29(1):16. PubMed ID: 35197069
[TBL] [Abstract][Full Text] [Related]
29. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
[TBL] [Abstract][Full Text] [Related]
30. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
Darr C; Krafft U; Hadaschik B; Tschirdewahn S; Sevcenco S; Csizmarik A; Nyirady P; Küronya Z; Reis H; Maj-Hes A; Shariat SF; Kramer G; Szarvas T
Urol Int; 2018; 101(1):65-73. PubMed ID: 29949801
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
32. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
34. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
[TBL] [Abstract][Full Text] [Related]
35. Mifepristone Has Limited Activity to Enhance the
Yang Y; Li X; Mamouni K; Kucuk O; Wu D
Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.
Wang N; Docherty FE; Brown HK; Reeves KJ; Fowles AC; Ottewell PD; Dear TN; Holen I; Croucher PI; Eaton CL
J Bone Miner Res; 2014 Dec; 29(12):2688-96. PubMed ID: 24956445
[TBL] [Abstract][Full Text] [Related]
37. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
38. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Zhang B; Li Y; Wu Q; Xie L; Barwick B; Fu C; Li X; Wu D; Xia S; Chen J; Qian WP; Yang L; Osunkoya AO; Boise L; Vertino PM; Zhao Y; Li M; Chen HR; Kowalski J; Kucuk O; Zhou W; Dong JT
Nat Commun; 2021 Mar; 12(1):1714. PubMed ID: 33731701
[TBL] [Abstract][Full Text] [Related]
39. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
[TBL] [Abstract][Full Text] [Related]
40. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
